Introduction
Synthetic biology has progressed rapidly over the last decade and is now positioned to impact important problems in energy and health. However, expansion into the clinical arena has been slowed by safety concerns and an absence of developing design criteria for in vivo genetic circuits. Accelerating high impact medical applications will require utilizing methods that interface directly with medical infrastructure, genetic circuits that function outside of the controlled lab setting, and safe and clinically-accepted microbial hosts.
A number of strains have been investigated for cancer therapy due to their ability to grow preferentially in tumors. These have included C. novyi, E. coli, V. cholorae, B. longum, and S. typhimurium [3] [4] [5] [6] [7] [8] . S. typhimurium has generated particular interest as they have exhibited safety and tolerance in a number of human clinical trials [9] [10] [11] [12] . These bacteria were initially shown to create anti-tumor effects through stimulation of the host immune system and by depletion of nutrients required for cancer cell metabolism. Production of therapeutic cargo was later added through genetic modifications. While these studies represent important advances in the use of bacteria for tumor therapies, the majority of existing efforts have relied on high-level expression that typically results in the delivery of high dosages, off-target effects, and development of host resistance 2. Add 500 μl PBS + 15% glycerol and homogenize using a Tissue-Tearor (BioSpec). Rinse the homogenizer 3 times with ethanol between samples. 3. Generate serial dilutions and plate for bacterial colony counting. To plate multiple dilutions on a single plate use pre-sectioned plates.
Representative Results
Using this protocol, we are able to generate data on the in vivo growth and gene expression dynamics of tumor targeted bacteria. The overall workflow is summarized in Figure 1 .
In the first stage, we inject bacteria (green) and image the animal using IVIS to measure gene expression with luminescence (blue) as a reporter.
Then, in the second stage, we excise, homogenize, and plate tumors for colony counts to determine the number of bacteria growing in the tumor.
Bioluminescence generated by bacterial strains is visualized using IVIS (Figure 2 ). Signal increases with injected dosage, with a minimum colonizing dosage around 5 x 10 5 (Figure 2A) . In all cases, attenuated bacteria are only able to either specifically colonize tumors or fail to grow in the mice. Signal is quantified using radiance units to normalize for exposure time, where typical values of 10^6 or greater are indicative of colonization.
For a given infection, signal increases with time over 24-48 hr ( Figure 2B ). The peak onset is around 36 hours after injection, but the timing may vary depending on the strain and plasmid being used. Be sure to position the mouse exactly the same way each time to ensure quantitative results.
In the next set of experiments, bacterial biodistrution is quantified to measure the growth of bacteria over time ( Figure 3 ). Viable bacteria in tumors are quantified by excising and homogenizing the tumor and plating at serial dilutions ( Figure 3A ). Other organs can also be quantified similarly. Here, we have used the spleen, since the tumor-spleen ratio is a typical measure of bacterial specificity 21, 22 .
These counts allow us to measure the bacterial population over time ( Figure 3B ). On the left, we can see that the number of bacteria grow steadily in the tumor throughout the duration of the experiment, with a doubling time of 1-3 hr, substantially slower than in batch culture experiments. This reduced rate is likely due to the poor nutrient conditions in the tumor environment. On the right, we have quantified the tumor-spleen ratio and observe that it increases throughout the experiment. This finding demonstrates specificity, in that the spleen counts are essentially constant while bacteria continue to grow in the tumor. 
Discussion
Using this procedure, we are able to generate time courses for the growth and gene expression dynamics of bacteria colonizing tumors. While these measurements are routinely performed in vitro in batch culture or microfluidics devices, they are much more difficult to perform in vivo.
There are several modifications that can be applied to these methods. While we used the OVCAR-8 cell line to generate our mouse models, a number of other cell lines may be used equivalently. For example, luciferized cell lines may be used that allow for 3D colocalization of tumor and bacterial luciferase channels. Additionally, while we used a bilateral hind flank model, a different number and locations of injection sites may be used to generate models to study different phenomena. For example, if tumor size is an important variable, serial dilutions of cells can be prepared and injected to different sites simultaneously, generating smaller-and larger-sized tumors. Finally, while we used S. typhimurium strain ELH430, other strains of S. typhimurium or other bacteria such as C. novyi, E. coli, V. cholorae, B. longum may be used equivalently with these methods, though the bacterial counts for injection may need to be adjusted.
The most critical steps in this protocol involve the creation of the mouse cancer model, and the preparation and injection of bacteria. For the creation of the cancer model, precision in the cell count and concentration, injection volume, and injection site placement will greatly enhance the consistency of the tumors generated. We have found that equivalently sized, shaped, and placed tumors create the most quantitatively comparable data. For the preparation of bacteria, it is critical to completely wash them prior to injection and to control for the bacteria concentration, volume, and injection site carefully. These steps are required to avoid excessive immunological impact of the injection, and to maintain quantitative comparison between separate mouse models. Since the number of bacteria that enter the tumor is a small fraction of the injected dose, variations in the number of injected bacteria between mice can result in dramatic differences on colony progression. For additional information, see several additional references on bacterial preparation for quantitative in vivo studies 3, 4 , While these techniques are highly adaptable to a variety of specific studies, some limitations exist for extending to certain applications. For example, intravenous delivery of high bacterial counts may not be desirable for certain bacteria and/or mouse models due to immunological impact. One alternative route of administration is oral delivery (gavage), a technique which is described on JoVE 23 . Additionally, time-lapse imaging can be quite labor-intensive depending on the specific experiment length, time-resolution, and equipment available. Automating the imaging process would alleviate many of these burdens, but also introduces new technical challenges. Mouse vitals such as heart rate, breath rate, and temperature must be continuously monitored by additional equipment. Additionally, for longer-term anesthesia, eye ointments must be used to maintain adequate moisture. Finally, the level of anesthetic delivered to the mouse must be continuously adjusted to maintain the proper depth of anesthesia. A closed-loop feedback control system that integrates mouse vital measurements with anesthetic delivery would greatly facilitate this process.
While synthetic biology has achieved much success 17, 19, 20 , applying engineered gene circuits to in vivo applications will require quantitative, in vivo time courses to inform design principles. S. typhimurium is an excellent strain for clinical synthetic biology for cancer therapy since it is similar to E. coli, specifically colonizes tumors, and has been shown safe in human clinical trials 6, 12, 14, 22 . Additionally, recent studies have found that many published circuits function in S. typhimurium without modification 24 . Using the experimental platform described here, we recently described how dynamic in vivo expression profiles can be programmed using the inherent instability of plasmid vectors 25 . In addition, recent research has developed novel methods for stably maintaining plasmid vectors in vivo 23 .
While luciferase is a common reporter used for in vivo imaging for its sensitivity 5 , there are examples of excellent studies on quantitative in vivo gene expression using GFP 26 . Using GFP would allow the researcher to study the spatial-temporal dynamics of individual bacteria in vivo. Additionally, while we used a subcutaneous model, extending these studies toward more relevant models of cancer would further increase their predictive power 7 . Future studies like this may enable a next generation of in vivo synthetic biology for clinical applications.
Developing both experimental and computational techniques in concert will be critical to engineering in vivo genetic circuits. Computational modeling can rapidly probe system parameters to explore potential outputs but must remain closely tied to experimental results to remain relevant. Thus far, these results have been difficult to obtain quantitatively, due in part to a lack of methods for studying genetic circuits in vivo.
Building on this platform, future applications will include engineered gene circuits that further extend the range of expression dynamics, sensing tumor-specific stimuli and self-regulating cargo production as needed. As the sophistication of these in vivo circuits increases, the requirements on quantitative data required to tune them will also increase. We believe that the methods described here, along with new innovations in longterm mouse imaging, will make this process possible.
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